TIMOTHY FURLONG: Open Payments
NPI 1629044557 · ATHENS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,556 in 82 payments from 13 companies in 2025. Trend: 2023 $1,169 · 2024 $1,253 · 2025 $1,556
Food & beverage: $1,556
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $347 |
| ABBVIE INC. | 20 | $269 |
| E.R. Squibb & Sons, L.L.C. | 12 | $174 |
| Neurocrine BioSciences, Inc. | 8 | $172 |
| Alkermes, Inc. | 8 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $107 |
| Lundbeck LLC | 4 | $90 |
| Teva Pharmaceuticals USA, Inc. | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
Products named: FANAPT, VRAYLAR, COBENFY, INGREZZA, REXULTI, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
